Compare IQV & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | CHRW |
|---|---|---|
| Founded | 1982 | 1905 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6B | 23.0B |
| IPO Year | 2013 | 1997 |
| Metric | IQV | CHRW |
|---|---|---|
| Price | $156.40 | $177.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 20 |
| Target Price | ★ $227.13 | $181.05 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.35% |
| EPS Growth | 4.67 | ★ 25.13 |
| EPS | ★ 7.84 | 4.83 |
| Revenue | $9,739,000,000.00 | ★ $14,869,380,000.00 |
| Revenue This Year | $6.77 | $5.07 |
| Revenue Next Year | $5.89 | $6.26 |
| P/E Ratio | ★ $20.30 | $37.41 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $134.65 | $86.58 |
| 52 Week High | $247.05 | $203.34 |
| Indicator | IQV | CHRW |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 49.08 |
| Support Level | N/A | $172.61 |
| Resistance Level | $193.26 | $187.09 |
| Average True Range (ATR) | 5.68 | 6.00 |
| MACD | -1.59 | 0.38 |
| Stochastic Oscillator | 7.16 | 51.52 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 60% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (30%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of transportation management services and a legacy produce-sourcing operation.